SkinBioTherapeutics plc SkinBiotix® technology successful in stability testing

Dr Cath O’Neill, CEO of SkinBioTherapeutics, commented:

“Demonstrating the extended stability of the cream formulation was a key step to commencing the human study. This remains on track to start this month.”

The information communicated within this announcement is deemed to constitute inside information as stipulated under the Market Abuse Regulations (EU) No. 596/2014 and has been arranged for release by Doug Quinn, CFO of the Company. Upon the publication of this announcement, this inside information is now considered to be in the public domain.

SkinBioTherapeutics plc (LON: SBTX), a life science company focused on skin health, today provided an update to its announcement of 16 August 2018. The stability criteria required for its human study has been met and the Company expects to commence the study in September as planned.

 

Click to view all articles for the EPIC:
Or click to view the full company profile:
    Facebook
    Twitter
    LinkedIn
    SkinBiotherapeutics Plc

    More articles like this

    SkinBiotherapeutics Plc

    SkinBioTherapeutics presenting at Made in the UK

    Made in the UK is a celebration of the diverse sectors of our manufacturing, design and scientific sectors that make Britain a global centre of innovation. Now in its fourth year, SkinBioTherapeutics is delighted to be participating

    Optibiotix Health Plc

    SkinBioTherapeutics PLC: First day of dealings

    SkinBioTherapeutics PLC (LON:SBTX, the “Company”), a life science company focused on skin health, announces the commencement of dealings in its Ordinary Shares on AIM at 8:00am yesterday under the ticker code SBTX and the ISIN number: